IDM Pharma Terminates Uvidem Deal With Sanofi-Aventis
This article was originally published in The Pink Sheet Daily
Executive Summary
Company plans to restructure after ending development deal for the investigational melanoma vaccine.
You may also be interested in...
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
Takeda May Resurrect IDM’s Bone Cancer Drug Mifamurtide In U.S.
Fate of IDM’s dendritic cell-based Uvidem and other cancer vaccines remains unclear after $75 million purchase.
FDA Finds IDM Pharma’s Junovan Study Lacking
FDA’s Oncologic Drugs Advisory Committee meets May 9 to review the osteosarcoma therapy.